^
Association details:
| Biomarker: | Chr del(9p) + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer
Published date:
05/27/2023
Excerpt:
...among NSCLCs with high PD-L1 expression (TPS ≥50%), chromosome 9p loss was associated with lower ORR (43% vs 6%, P<0.0001), shorter mPFS (6.4 vs 2.6 months, P=0.0006), and shorter mOS (30.2 vs 14.3 months, P=0.0008) to immunotherapy compared to NSCLCs without 9p loss....Nonsquamous NSCLCs with high aneuploidy and chromosome 9p loss have a distinct tumor immune microenvironment and less favorable outcomes to ICIs.
DOI:
10.1016/j.jtho.2023.05.019
Source:
Title:
Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer.
Published date:
01/28/2023
Excerpt:
A total of 765 advanced nonsquamous NSCLCs with available FAA values were treated with ICIs….Compared to NSCLCs without chromosome 9p loss (N=452), those with 9p loss (N=154), had a lower ORR (28.1% vs 7.8%, P<0.001), a shorter mPFS (4.1 vs 2.3 months, P<0.001), and a shorter mOS (18.0 vs 9.6 months, P<0.001) to immunotherapy. Chromosome 9p loss in tumors with PD-L1 TPS ≥50% resulted in a significantly lower ORR (6% vs 43%, P<0.001), a significantly shorter mPFS (2.6 vs 6.4 months, HR: 1.94; P<0.001), and a significantly shorter mOS (14.3 vs 30.2 months, HR: 1.98; P<0.001) compared with NSCLCs with intact 9p arm and a high PD-L1 expression.
